Company / Free Cash Flow
Matinas BioPharma Holdings, Inc. Free Cash Flow History
FY2015-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Free Cash Flow
-$20.0M
FY2023
5-year range
-$20.0M / -$15.5M
FY2019-FY2023
Trend
-29.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Free Cash Flow has fluctuated over the past 9 years, ranging from -$20M in FY2023 to -$6M in FY2016.
Based on SEC 10-K filings.
-$20M in FY2023.
Declined from -$15M to -$20M over the past 2 years.
Free Cash Flow over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2023, free cash flow decreased 29.5% year-over-year.
- Peak free cash flow was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Free Cash FlowValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | - | - |
| FY2023 | -$20.0M | -29.5% |
| FY2022 | -$15.5M | +0.0% |
| FY2021 | -$15.5M | +10.9% |
| FY2020 | -$17.4M | -60.0% |
| FY2019 | -$10.9M | +12.5% |
| FY2018 | -$12.4M | -57.2% |
| FY2017 | -$7.9M | -29.0% |
| FY2016 | -$6.1M | +22.5% |
| FY2015 | -$7.9M | - |
As of FY2023 · SEC 10-K · Updated Jun 24, 2026